Lynx Biosciences

Lynx Biosciences (LynxBio) is a biotechnology firm focused on immuno-oncology and immunology therapies, currently operating from San Diego where it is an incubatee at Johnson & Johnson's JLABS facility. The company was founded in 2017 by Dr. Chorom Pak, who conceived the idea during her Ph.D. studies in molecular and cellular pharmacology at the University of Wisconsin-Madison. The founding concept stemmed from a microfluidic chip project, which evolved into LynxBio's core technology. Dr. Pak's experience includes serving as the clinical and R&D lead at Cellectar Biosciences, where she co-developed a radiotherapeutic for hematological malignancies that advanced to Phase 2 clinical trials. Originally established in Madison, Wisconsin, the company relocated to San Diego in 2017 to leverage the city's extensive biotech cluster, resources, and access to investors.

The company's business model revolves around strategic partnerships with biopharmaceutical companies to accelerate drug discovery and development. It generates revenue by collaborating with these partners, including top-ten biopharma firms, to identify therapeutic candidates and predictive biomarkers. LynxBio also develops its own internal pipeline of treatments centered on novel signaling pathways. Its primary clients are biopharma and technology companies seeking to advance their drug discovery programs, with an initial focus on immuno-oncology.

LynxBio's core offering is a proprietary *ex vivo* disease biology platform that provides a systems-level understanding of human biology to speed up the development of new therapies. This platform, which includes the MicroC3™ system, combines patient-derived cell assays, automated microfluidics, multi-omic readouts (cytomics, proteomics, transcriptomics, genomics), and deep learning analytics. It is designed to analyze the complex interactions between tumor cells and the immune environment by integrating dynamic, functional data from primary patient models. This approach allows for the rapid identification and confirmation of druggable targets, aiming to improve the translation of preclinical findings to clinical success in areas like hematological cancers and immunotherapies.

Keywords: immuno-oncology, drug discovery, multi-omics, ex vivo platform, personalized medicine, cancer biology, biopharmaceutical partnerships, therapeutic development, microfluidics, deep learning analytics, patient-derived models, tumor microenvironment, predictive biomarkers, hematological cancers, immunology therapies, cell-based assays, systems biology, oncology research, biotech, drug development